bioMérieux HPV test
This article was originally published in The Gray Sheet
Executive Summary
Paris firm launches human papillomavirus (HPV) diagnostic in Europe April 23. The test, which uses NorChip's m-RNA-based Pre-Tect HPV-proofer on bioMérieux's NucliSENS EasyQ platform, is the result of a recently signed license agreement intended to expand the latter firm's footprint in the infectious disease diagnostic market (1"The Gray Sheet" Jan. 22, 2007, p. 21). bioMérieux's molecular diagnostic enables assessment of the virus' oncogenicity, a feature unattainable with viral DNA tests, the firm says. Digene's DNAwithPap is the only FDA-approved test for HPV, the primary cause of cervical cancer. Roche (Amplicor), Gen-Probe (Aptima), Ventana (Inform) and Third Wave Technologies are developing HPV tests...